Faculty Opinions recommendation of Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature June 28, 2021 Michael A. Rogawski
A single dose of psilocybin (0.143 mg/kg) reduced weekly migraine days by an average of 1.65 days per week over two weeks, significantly more than placebo (0.15 days per week). The reduction in migraine frequency was not linked to the intensity of acute psychedelic effects during the session. Ten adults with migraine completed the double-blind, placebo-controlled, crossover trial. Psilocybin was well-tolerated with no serious adverse events. The findings suggest a lasting therapeutic effect after one dose, distinct from the immediate psychological experience, pointing to a separate mechanism that warrants further study in migraine and other conditions.